重藥控股(000950.SZ)：重慶醫藥擬參與競買重鹽集團所持化醫財務公司10%股權
格隆匯12月6日丨重藥控股(000950.SZ)公佈，公司擬通過控股子公司重慶醫藥(集團)股份有限公司(“重慶醫藥”)擇機以不超過約1.23億元，參與公開競買重慶市鹽業(集團)有限公司(“重鹽集團”)持有的重慶化醫控股集團財務有限公司(“化醫財務公司”)10%股權。
重鹽集團原為公司間接控股股東重慶化醫控股(集團)公司(“化醫集團”)全資子公司，於2019年5月變更為中鹽西南鹽業有限公司(“中鹽西南”)全資子公司；中鹽西南為中國鹽業股份有限公司(中鹽股份)控股子公司，化醫集團參股。重鹽集團實際控制人由化醫集團變更為中鹽股份後，為進一步聚焦主業發展，擬退出所參股化醫財務公司，並通過公開掛牌方式在重慶聯合產權交易所集團股份有限公司(“重慶聯交所”)轉讓所持化醫財務公司10%股權。
公司認為化醫財務公司盈利能力良好，可以持續穩定地為公司帶來投資回報，同時，能夠幫助公司進一步提升資金整合效率，公司擬通過控股子公司重慶醫藥擇機以不超過約1.23億元，參與公開競買重鹽集團持有的化醫財務公司10%股權。
重慶化醫控股集團財務有限公司經營範圍：對成員單位辦理財務和融資顧問、信用鑑證及相關的諮詢、代理業務；協助成員單位實現交易款項的收付；經批准的保險代理業務；對成員單位提供擔保；辦理成員單位之間的委託貸款及委託投資；對成員單位辦理票據承兑與貼現；辦理成員單位之間的內部轉帳結算及相應的結算、清算方案設計；吸收成員單位的存款；對成員單位辦理貸款及融資租賃；從事同業拆借；承銷成員單位的企業債券；除股票投資以外的有價證券投資；成員單位產品的買方信貸。(依法須經批准的項目，經相關部門批准後方可開展經營活動)
此次交易，化醫財務公司除重鹽集團外其他股東已出具放棄優先購買權承諾函。此次交易完成後，重慶醫藥增加持有化醫財務公司10%的股權，合計持有財務公司30%股權，不會導致公司合併報表範圍發生變更。
化醫財務公司具備開展多項金融業務的資質，經營狀況良好，資產優良。此次交易完成後，可以藉助化醫財務公司進一步提升公司資金管控效率，同時有利於資源的有效整合，進一步拓寬上市公司的經營業態，提升公司的整體競爭力和未來盈利能力，符合上市公司發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
